Side Effects of Allergy Shots: Full Taxonomy From Local to Systemic

Local injection-site reactions are by far the most common side effect of allergy shots. Published studies report local reactions — redness, swelling, warmth, and itching at the needle site — in 26-86% of patients receiving SCIT (James & Bernstein 2017, Curr Opin Allergy Clin Immunol). The wide range reflects differing measurement criteria across studies. Most local reactions are small (under a quarter in diameter) and resolve within hours. Large local reactions, where swelling exceeds 2.5 cm and persists beyond 24 hours, are less common, occurring in 0.4-5.3% of injections depending on the definition used. Both types are orders of magnitude more common than systemic reactions, which affect about 1 in 500-1,000 injection visits.

Most systemic reactions to allergy shots are mild. Of the 8,502 systemic reactions reported across 8.1 million injection visits in the AAAAI/ACAAI National Surveillance Study (Bernstein 2010, Ann Allergy), 74% were WAO Grade 1 — affecting only one organ system, such as generalized hives or nasal symptoms without lower-respiratory or cardiovascular involvement. Grade 2 (multiple organ systems) accounted for 23%, and Grade 3 (severe lower-respiratory or laryngeal) accounted for 3%. Grade 4 anaphylaxis — the most serious non-fatal category — occurs at approximately 1 per 160,000 visits, and fatal reactions have fallen to approximately 1 per 9 million visits in the modern surveillance era (Epstein 2019).

Most patients find that side effects improve over time as the immune system adapts to the injected allergen doses. During the build-up phase, when doses increase weekly, mild and moderate systemic reaction rates per injection are higher than during the maintenance phase. However, the picture is nuanced: 59% of confirmed fatalities in the Bernstein 2004 fatality survey occurred during maintenance, not build-up — often in association with new-vial transitions or pollen season exposure. So while the overall side-effect burden typically decreases as you approach and sustain maintenance doses, vigilance remains important throughout treatment. Patients with recurrent large local reactions during any phase should report them to their allergist, as the REPEAT Study (Calabria 2011) found a 41.7% systemic reaction rate in this subgroup.

WAO Grade 1 is a mild systemic reaction affecting only one organ system — for example, generalized hives without breathing difficulty, or nasal symptoms (sneezing, congestion) without skin or lower-respiratory involvement. It represents 74% of all systemic events and is the most common grade by far (Bernstein 2010). WAO Grade 4 is anaphylaxis: respiratory failure (with or without loss of consciousness) or hypotension (with or without loss of consciousness). Grade 4 occurs at approximately 1 per 160,000 injection visits (Bernstein/Epstein 2020, Allergy Asthma Proc). Both grades require clinic staff to be notified immediately, but the management differs significantly — Grade 4 requires immediate epinephrine injection and emergency services.

This question has a nuanced answer in the clinical literature. A single large local reaction does not reliably predict a subsequent systemic reaction — the 2011 AAAAI/ACAAI Practice Parameter explicitly states this and cites Tankersley 2000 and the LOCAL Study (Calabria 2009) as supporting evidence. However, a pattern of recurrent large local reactions does appear to identify a higher-risk subset. The REPEAT Study (Calabria 2011, Ann Allergy) found that 41.7% of patients with frequent recurrent large local reactions experienced at least one systemic reaction during follow-up, compared to 10.7% of patients without recurrent reactions. This means an isolated large local reaction should not cause alarm, but persistent recurrence warrants a conversation with your allergist about dose adjustment or pretreatment strategies.

Cluster build-up schedules — where multiple injections are given per visit to reach maintenance dose faster — carry roughly three times the per-injection systemic reaction rate of conventional schedules. A Johns Hopkins study (Tversky 2022, JACI; n=91) found systemic reaction rates of 0.69% per injection with standard schedules versus 2.29% per injection with cluster build-up (incidence rate ratio 3.3, 95% CI 1.5-7.3). A multicenter cluster cohort reported a 10.9% per-patient systemic reaction rate during the accelerated phase, with 11% of those reactions classified as WAO Grade 3. Cluster protocols typically require antihistamine premedication, vital-signs checks between same-day injections, and extended post-visit monitoring to manage this elevated short-term risk.

Yes — approximately 15% of all systemic reactions from allergy shots are delayed, beginning more than 30 minutes after the injection (Epstein 2011, Ann Allergy; Epstein 2019, JACI Pract). This is why the 30-minute observation window, while capturing the great majority of reactions, does not eliminate all risk after your 30-minute observation window ends. A single-center analysis by Larenas-Linnemann (2017, JACI Pract) found even higher delayed-reaction rates of 52.8% in their 10-year series — suggesting significant practice-level variation. Patients should monitor themselves for new symptoms (hives, throat tightness, wheezing, dizziness) for 2-4 hours after each injection, particularly during build-up phase, after starting a new extract vial, or during their relevant pollen season.